Immune Resistance in Lung Adenocarcinoma

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

(2020) Maud Mayoux et al.   Science Translational Medicine

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma

(2019) Ioannis Lilis et al.   OncoImmunology

Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer

(2019) Jair Bar et al.   LUNG CANCER

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors

(2019) Patrícia Dias Carvalho et al.   Cancers

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T

(2018) Dok Yoon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion

(2018) Antonia Marazioti et al.   Nature Communications

Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments

(2018) Xufan Li et al.   OncoImmunology

Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma

(2017) Tomonari Kinoshita et al.   EUROPEAN JOURNAL OF CANCER

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutant KRAS promotes malignant pleural effusion formation

(2017) Theodora Αgalioti et al.   Nature Communications

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer

(2017) Richard D. Hall et al.   Cancer Control

Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance

(2016) B. Bonavida et al.   ANNALS OF ONCOLOGY

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

Lung Cancer Subtypes Generate Unique Immune Responses

(2016) Stephanie E. Busch et al.   JOURNAL OF IMMUNOLOGY

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment

(2016) Tiffany G. Huynh et al.   Journal of Thoracic Oncology

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆

(2016) Megan L. Hames et al.   LUNG CANCER

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer

(2016) Allyson G. McLoed et al.   Cell Reports

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

(2016) S. Zdanov et al.   Cancer Immunology Research

Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib

(2015) Shingo Miyamoto et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Mast cells mediate malignant pleural effusion formation

(2015) Anastasios D. Giannou et al.   JOURNAL OF CLINICAL INVESTIGATION

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs

(2015) Sharad K. Sharma et al.   JOURNAL OF IMMUNOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

(2015) E. M. Tricker et al.   Cancer Discovery

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

(2015) Meghan Shea et al.   Therapeutic Advances in Respiratory Disease

Tumorigenic Th17 cells in oncogenic Kras-driven and inflammation-accelerated lung cancer

(2015) Seon Hee Chang   OncoImmunology

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

(2014) C. Costa et al.   CLINICAL CANCER RESEARCH

Cigarette Smoke-Induced Oxidative Stress Suppresses Generation of Dendritic Cell IL-12 and IL-23 through ERK-Dependent Pathways

(2014) P. R. Kroening et al.   JOURNAL OF IMMUNOLOGY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Entering the mainstream of cancer treatment

(2014) Steven A. Rosenberg   Nature Reviews Clinical Oncology

T helper 17 cells play a critical pathogenic role in lung cancer

(2014) S. H. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

(2014) Ji-Won Kim et al.   Cancer Research and Treatment

Annual number of lung cancer deaths potentially avertable by screening in the United States

(2013) Jiemin Ma et al.   CANCER

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

Lung cancer: potential targets for immunotherapy

(2013) Eric Tartour et al.   Lancet Respiratory Medicine

Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer

(2012) Lauren J. Bayne et al.   CANCER CELL

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Myeloid suppressor cells and immune modulation in lung cancer

(2012) Minu K Srivastava et al.   Immunotherapy

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

(2012) Suzanne Ostrand-Rosenberg et al.   SEMINARS IN CANCER BIOLOGY

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis

(2011) R. Zaynagetdinov et al.   JOURNAL OF IMMUNOLOGY

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

(2011) Trever G. Bivona et al.   NATURE

Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes

(2011) R Zaynagetdinov et al.   ONCOGENE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Receptor for Advanced Glycation End-Products Signals through Ras during Tobacco Smoke–Induced Pulmonary Inflammation

(2010) Paul R. Reynolds et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Chemokines in cancer related inflammation

(2010) Paola Allavena et al.   EXPERIMENTAL CELL RESEARCH

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer

(2010) Katsuhiko Shimizu et al.   Journal of Thoracic Oncology

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells

(2009) M. Santisteban et al.   CANCER RESEARCH

Targeted therapies for non-small cell lung cancer

(2009) Wolfram C.M. Dempke et al.   LUNG CANCER

A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis

(2009) Courtney A. Granville et al.   PLoS One

Inflammation in the development of lung cancer: epidemiological evidence

(2008) Eric A Engels   Expert Review of Anticancer Therapy

Suppression of pulmonary innate host defence in smokers

(2008) C Herr et al.   THORAX